Validity and safety of sputum induction by inhaled uridine 5'-triphosphate.
Inhalation of hypertonic saline during sputum induction causes bronchoconstriction. We studied the validity and safety of sputum induction by uridine 5'-triphosphate (UTP). Sputum was induced by a 5-min inhalation of hypertonic saline (3%) on Day 1 and UTP (5 mg/ml in 0.9% saline) on Days 8 and 15 in 16 healthy subjects and 16 patients with mild-to-moderate asthma. Inhaled UTP produced twofold greater amounts of sputum than did hypertonic saline. There were significant differences in oxygen desaturation and bronchoconstriction during the procedure between the two methods: the maximal fall in Sa(O(2)), the AUC of the Sa(O(2))-time response, and the fall in PEF were less in the subjects who received UTP than in those who received hypertonic saline. Sputum total cell and differential cell counts, with a high proportion of eosinophils in asthmatics, were similar between specimens obtained by hypertonic saline and UTP. When we compared two consecutive measurements on the UTP-induced sputum samples, the reproducibility calculated by the intraclass correlation coefficient was high for the proportion of eosinophils, neutrophils, and macrophages. Therefore, inhalation of UTP aerosols may provide an effective, relatively noninvasive, valid, and reproducible method of sputum induction for the assessment of airway inflammation in asthma.


BACKGROUND
uridine triphosphate; induced sputum; airway inflammation; bronchoconstriction; asthma
Tamaoki
J
J
First Department of Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Kondo
M
M
Kuroda
H
H
Aoshiba
K
K
Takeyama
K
K
Nakata
J
J
Nagai
A
A
D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D001249:Asthma / Q000175:diagnosis* / Q000473:pathology; D016084:Bronchoconstriction; D005260:Female; D006801:Humans; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D013183:Sputum; D014544:Uridine Triphosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D000336:Aerosols; D014544:Uridine Triphosphate